Latest filing published 21 Jul 2025 for Blueprint Medicines Corp. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Percy H. Carter, listed as senior executive, appears in our data through filings on Blueprint Medicines Corp shares, published by SEC (Form 4). Over a trading history stretching from 1 June 2021 to 17 July 2025, the count stands at 16 filings.
Sales make up the whole of the open-market record (9 sales, €1.5M). Outside the open market, there are 7 share grants. Since January 2025: no purchases and 3 sales on the market.
The latest filing, published on 21 July 2025, reports a share grant in Blueprint Medicines Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations